Company news
Argent Biopharma Ltd news in 2020
Argent Biopharma Ltd's news releases, calls and decks from 2020, newest first.
ArtemiC Phase II Clinical Trial Results
December 14, 2020
Prospectus
November 23, 2020
MGC pharma completes acquisition of telehealth platform MCC
November 22, 2020
Further successful results from glioblastoma research
November 16, 2020
Completion of phase II clinical trial on COVID-19 patients
November 4, 2020
September Quarterly Activity and Cashflow Report
October 26, 2020
Mgc pharma delivers record consecutive weekly sales growth
October 19, 2020
ArtemiC histology on rats confirm no pathological impact
October 14, 2020
First high THC products shipped direct to Brazil patients
October 11, 2020
MGC pharma launches CannEpil app
October 6, 2020
Update on ArtemiC phase II trial on COVID-19 patients
September 28, 2020
Mxc welcomes new FCA guidance for cannabis sector in the UK
September 20, 2020
Mxc well positioned for tga down-schedule of cbd products
September 13, 2020
$15M finance facility to fund revenue growth for key markets
September 10, 2020
Appendix 4E and Preliminary Unaudited Financial Report
August 31, 2020
JV to be established for registration of ArtemiC in Russia
August 24, 2020
COVID-19 Interim Trial Results Meet All Primary Objectives
August 20, 2020
UK distribution agreement signed for MGC Pharma medicines
August 14, 2020
Study confirms effectiveness of ArtemiC on human immune cell
August 6, 2020
Trading halt
August 5, 2020
June Quarterly Activity and Cashflow Report
July 31, 2020
Reinstatement to Official Quotation
July 26, 2020
Suspension from Official Quotation
July 24, 2020
MGC Pharma to acquire 100% of Medicinal Cannabis Clinic
July 19, 2020
MXC Cannabis Research Permit Granted for RMIT Programs
July 13, 2020
MGC Pharma awarded Import Licence by Office of Drug Control
July 7, 2020
COVID-19 Clinical Trial Site Expansion into India
July 2, 2020
MXC Awarded 3-year EU GMP Manufacturing Licence
June 23, 2020
Sale of MGC Nutra to US CBD and Hemp Wellness Company
June 17, 2020
Binding Term Sheet for distribution of CannEpil in Israel
June 14, 2020
3,250 Prescriptions Milestone Surpassed
June 1, 2020
Ethics Committee Approval for CannEpil Phase IIb Trial
May 25, 2020
Binding Term Sheet Signed for Distribution of ArtemiC
May 12, 2020
Voluntary Suspension
May 10, 2020
Phase II Clinical Trial on COVID-19 Patients Commenced
May 5, 2020
March Quarterly Activity and Cashflow Report
April 29, 2020
Second Ethics Committee Approval for Phase II COVID-19 Trial
April 28, 2020
MGC Pharma Secures Commitments for $3.5m Placement
April 27, 2020
Successful Research Results for MGC on Glioblastoma
April 22, 2020
Phase II Clinical Trial on Patients Diagnosed with COVID-19
April 17, 2020
Pause In Trade
April 16, 2020
MGC Pharma Signs Agreement Targeting Anti-Viral Treatments
April 15, 2020
MGC Pharma COVID-19 Business and Operations Update
April 6, 2020
Patients Begin Treatment in Clinical Trial of CogniCann
March 8, 2020
Binding Amendment to Supply Agreement with ONIX Brazil
March 2, 2020
Commercial Supply Deal Signed for First Products into Poland
February 26, 2020
85% Increase in Order Volume of New Prescription Products
February 20, 2020
Security Purchase Plan- Offer Document
February 17, 2020
MGC Pharma announces $1m Strategic Placement and $3m SPP
February 16, 2020
Agreement Signed with Leading Peruvian Distributor
January 27, 2020
Decks in 2020
- MGC Pharmaceuticals — Investor Presentation (January 2020)
Investor deck · 25 slides · January 2020